Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“I find MedCity News a great resource for taking the pulse of the market and sourcing potential investment opportunities.”

Bernie Rudnick, Angel investor and advisor, CapGenic Advisors, LLC


Sign up for our daily newsletter


Health IT company that helps make sense of genomics data raises $10M

9:20 am by | 0 Comments

syapse

 

 

Syapse, a healthcare data analytics company that helps health systems crunch and analyze genomics data and clinical data to support treatment decisions has closed a Series B round. It will go toward expanding the company’s sales and marketing muscle and advance clinical development.

Advertisement

Safeguard Scientifics led the $10 million Series B round, and an earlier investor, Social + Capital Partnership, a venture fund launched by former Facebook Vice President Chamath Palihapitiya, also participated, according to a company statement. It follows a Series A round raised last year and brings the total amount raised to $14.5 million.

The company’s platform integrates data from electronic medical records, molecular testing labs, imaging and billing systems, and is agnostic to the data source or system, according to its website. Clinicians use the information it generates as part of the conclusions they form on diagnoses and treatment.

The use of big data platforms to access siloed data and develop a better understanding of the best treatment options for each patient has been a growing source, particularly in cancer treatment.

Toward the end of last year it rolled out a platform for laboratories called Syapse for Labs to help labs order tests online, automatically generate reports, update reports with new information, and approve and deliver them.

Syapse has worked on collaborative partnerships to help grow the company. One example is Intermountain Cancer Genomics. The collaboration involves providing a comprehensive service for oncologists that involves tumor genome profiling, personalized treatment planning and drug procurement.

Earlier this year, it partnered with N-of-One, a precision medicine company that matches patient-specific tumor molecular profiling data with diagnostic technologies and therapeutic options. It will make N-of-One clinical interpretations available to hospitals and laboratories through an interface in the Syapse platform.

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Stephanie Baum

By Stephanie Baum

Stephanie Baum is the East Coast Innovation Reporter for MedCityNews.com. She enjoys covering healthcare startups across health IT, drug development and medical devices and innovations deployed to improve medical care. She graduated from Franklin & Marshall College in Pennsylvania and has worked across radio, print and video. She's written for The Christian Science Monitor, Dow Jones & Co. and United Business Media.
Visit website | More posts by Author

0 comments